| 0.285 -0.022 (-7.17%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.04 | 1-year : | 1.49 |
| Resists | First : | 0.89 | Second : | 1.27 |
| Pivot price | 0.3  |
|||
| Supports | First : | 0.27 | Second : | 0.22 |
| MAs | MA(5) : | 0.29  |
MA(20) : | 0.31 |
| MA(100) : | 1.11 |
MA(250) : | 1.84 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 23.2 |
| RSI | RSI(14): 27.7 |
|||
| 52-week | High : | 4.34 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ERNA ] has closed above bottom band by 35.9%. Bollinger Bands are 79.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.31 - 0.31 | 0.31 - 0.31 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.29 - 0.29 | 0.29 - 0.29 |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Fri, 27 Feb 2026
ERNA Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 26 Feb 2026
Ernexa Therapeutics updates investor presentation, posts Exhibit 99.1 on website - TradingView
Fri, 20 Feb 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewswire
Tue, 17 Feb 2026
Ernexa therapeutics ten percent owner Cherington buys $2m in stock - Investing.com
Wed, 11 Feb 2026
Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView
Fri, 06 Feb 2026
Ernexa Therapeutics Inc. Announces Pricing of $10.5 Million Public Offering of Common Stock and Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 5.33e+006 (%) |
| Held by Institutions | 31.8 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.85e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -992 % |
| Return on Assets (ttm) | 200 % |
| Return on Equity (ttm) | -89.3 % |
| Qtrly Rev. Growth | 1000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 148.36 |
| Qtrly Earnings Growth | 56.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 4.28 |
| Dividend | 0 |
| Forward Dividend | 134360 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|